Clinical Trial Update: A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety of inclacumab in sickle cell disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Inclacumab

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Status: TERMINATED